Hemcheck Sweden AB has filed a patent application regarding a new product for the blood gas market. This is according to the current strategy to protect the company’s intellectual property. Development work has been done during the spring to attain functioning prototypes, and the product would in a future commercialization effort be a complement to the current product portfolio.

Hemcheck cannot release more information about the patent application today. The application will be handled according to current patent application processes. Hemcheck will, as soon as it is possible, release more information to the market.

– Its truly positive that we have been able to develop the prototypes during the spring and that we now have filed this patent application. For a company like Hemcheck its important to have strong intellectual property protection. We hope we can take this product to commercialization and attain the required CE-marking, since we believe this can strengthen our offering regarding quality assurance of blood gas analyses, says Joen Averstad, CEO of Hemcheck.

For further information contact:

Hemcheck Sweden AB (publ)

Joen Averstad, CEO

Tel: +46 76 108 8191

Email: joen.averstad@hemcheck.com

About Hemcheck

Hemcheck Sweden AB, founded in 2010, produces and commercializes a patented CE-marked concept for point of care hemolysis detection. The concept consists of disposable tests as well as readers that can very quickly, directly upon sampling, identify hemolysed blood samples in vacuum tubes and blood gas syringes. Hemolysis, ruptured red blood cells, is the most common reason globally why blood samples cannot be analyzed accurately. Hemcheck’s goal is to contribute to improved healthcare by offering user-friendly services for the detection of hemolysed blood samples in direct connection with blood sampling. By doing so, Hemcheck can contribute to increased patient safety, more efficient processes and lower costs. The company is based in Karlstad and is listed on the Nasdaq First North Growth Market.

FNCA Sweden AB, 08-528 00 399, info@fnca, is the Certified Adviser to the company.